Beyond Air, Inc. (XAIR) Tops Q4 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AAPL
2. AMD
3. CRWD
4. PLTR
5. DOX
6. VRTX
7. CHKP
8. ON
9. HNGE
10. INSP

Go back to Beyond Air, Inc. (XAIR) Tops Q4 EPS by 2c

Beyond Air, Inc. (XAIR) Announces Positive Preclinical Data Supporting High Concentration Nitric Oxide as a Potential Treatment for Solid Tumors

June 22, 2020 9:05 AM EDT

Beyond Air, Inc. (NASDAQ: XAIR), a clinical-stage medical device and biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO (gNO) for the treatment of solid tumors, today announced in vivo and in vitro data that show the potential efficacy of high concentration nitric oxide in ablation of solid tumors. The data were presented by Dr. Hila Confino of Beyond Air in an e-poster poster titled, Gaseous Nitric Oxide at High Concentration is a... More